Clinical Trial Update: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study [Phase 3]

View source ↗

Summary

A Phase 3 extension and crossover vaccination study evaluating immune response and safety of an RSV vaccine in adults aged 60+ who participated in a previous RS…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• GlaxoSmithKline RSV vaccine (investigational or specified in study)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING